(Q37989489)

26 August 2017

title

Prediction of warfarin dose: why, when and how? (English)

1 reference

26 August 2017

1 reference

2

Mia Wadelius

1 reference

26 August 2017

Niclas Eriksson

1

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

429-440

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

International Normalized Ratios (INR): the first 20 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Guidelines on oral anticoagulation with warfarin - fourth edition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Optimal loading dose for the initiation of warfarin: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Vitamin K supplementation to decrease variability of International Normalized Ratio in patients on vitamin K antagonists: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Kidney function influences warfarin responsiveness and hemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Warfarin dosing in patients with impaired kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Emergency hospitalizations for adverse drug events in older Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Understanding the pharmacogenetic approach to warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Genetic warfarin dosing: tables versus algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A randomized controlled trial of genotype-based Coumadin initiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Integration of genetic, clinical, and INR data to refine warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

Pharmacoeconomic evaluation of warfarin pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.184

21 January 2018

Identifiers

DOI

10.2217/PGS.11.184

1 reference

26 August 2017

1 reference